FR09C0040I2 - - Google Patents

Info

Publication number
FR09C0040I2
FR09C0040I2 FR09C0040C FR09C0040C FR09C0040I2 FR 09C0040 I2 FR09C0040 I2 FR 09C0040I2 FR 09C0040 C FR09C0040 C FR 09C0040C FR 09C0040 C FR09C0040 C FR 09C0040C FR 09C0040 I2 FR09C0040 I2 FR 09C0040I2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR09C0040C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bial Portela Ca Sa
Original Assignee
Bial Portela Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20085522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR09C0040(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bial Portela Ca Sa filed Critical Bial Portela Ca Sa
Publication of FR09C0040I1 publication Critical patent/FR09C0040I1/fr
Application granted granted Critical
Publication of FR09C0040I2 publication Critical patent/FR09C0040I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR09C0040C 1995-06-30 2009-08-26 Active FR09C0040I2 (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PT101732A PT101732B (pt) 1995-06-30 1995-06-30 Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso

Publications (2)

Publication Number Publication Date
FR09C0040I1 FR09C0040I1 (en:Method) 2009-10-30
FR09C0040I2 true FR09C0040I2 (en:Method) 2011-04-01

Family

ID=20085522

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0040C Active FR09C0040I2 (en:Method) 1995-06-30 2009-08-26

Country Status (22)

Country Link
US (1) US5753646A (en:Method)
EP (1) EP0751129B3 (en:Method)
JP (2) JP3852984B2 (en:Method)
KR (1) KR100376603B1 (en:Method)
CN (1) CN1070853C (en:Method)
AR (1) AR003962A1 (en:Method)
AT (1) ATE173468T3 (en:Method)
AU (1) AU705388B2 (en:Method)
BR (1) BRPI9602933B8 (en:Method)
CA (1) CA2180301C (en:Method)
DE (2) DE69600985T3 (en:Method)
DK (1) DK0751129T6 (en:Method)
ES (1) ES2124612T7 (en:Method)
FR (1) FR09C0040I2 (en:Method)
HU (1) HU221382B1 (en:Method)
NL (1) NL300406I1 (en:Method)
PL (1) PL185476B1 (en:Method)
PT (1) PT101732B (en:Method)
RU (1) RU2168502C2 (en:Method)
SI (1) SI0751129T1 (en:Method)
TR (1) TR199701734T1 (en:Method)
WO (1) WO1997002250A1 (en:Method)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930058D0 (en) 1999-12-20 2000-02-09 Novartis Ag Organic compounds
GB0111566D0 (en) 2001-05-11 2001-07-04 Portela & Ca Sa Method for preparation of (s)-(+)-and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azephine-5-carboxamide
GB0112812D0 (en) * 2001-05-25 2001-07-18 Portela & Ca Sa Mthd for preparation of 10, 11-dihydro-10-hydroxy-5H-dibenz/B,F/azepine-5-c arboxamide and 10,11-dihydro-10-oxo-5H-dibenz/B,F/azepine-5-carb oxamide therefrom
RU2189225C1 (ru) * 2001-09-14 2002-09-20 Нестерук Владимир Викторович Лекарственное средство на основе карбамазепина
PT1446383E (pt) * 2001-11-12 2008-12-29 Novartis Ag Mono-hidroxicarbamazepina para uso na preparação de um medicamento para o tratamento de perturbações do foro afectivo e perturbações da atenção e dores neuropáticas
EP1528927A1 (en) 2002-08-06 2005-05-11 Novartis AG Use of carboxamides for the treatment of tinnitus
GB0223224D0 (en) * 2002-10-07 2002-11-13 Novartis Ag Organic compounds
GB0303613D0 (en) * 2003-02-17 2003-03-19 Novartis Ag Use of organic compounds
BRPI0407569A (pt) * 2003-02-17 2006-02-14 Novartis Ag uso de s-10-hidróxi-10, 11-diidro-carbamazepina para o tratamento de ansiendade e distúrbios bipolares
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
TW200502222A (en) 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
GB2401605A (en) * 2003-05-12 2004-11-17 Portela & Ca Sa Method for racemisation of (S)-(+)- and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide and optically enriched mixtures thereof
GB2416167A (en) * 2004-07-13 2006-01-18 Portela & Ca Sa Chiral inversion and esterification of (S)- and (R)-10-hydroxy-dibenzazepine carboxamides
ITMI20042230A1 (it) * 2004-11-19 2005-02-19 Farchemia Srl Procedimento per la preparazione della 10,11-diidro-10 idrossi-5h-dibenz-b,f-azepin-5carbossiammide
GB2422149A (en) * 2005-01-14 2006-07-19 Portela & Ca Sa Process for the preparation of 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
JP2008540405A (ja) * 2005-05-06 2008-11-20 ポルテラ・アンド・シーエー・エスエー 酢酸エスリカルバゼピン及び使用方法
RU2417085C2 (ru) * 2005-05-06 2011-04-27 Биал-Портела Энд Ка, С.А. Эсликарбазепина ацетат и способы его применения
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2006120501A1 (en) * 2005-05-06 2006-11-16 Portela & C.A., S.A. Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0515690D0 (en) 2005-07-29 2005-09-07 Portela & Ca Sa Asymmetric catalytic reduction
GB0517740D0 (en) * 2005-08-31 2005-10-12 Novartis Ag Organic compounds
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
GB2437078A (en) * 2006-04-11 2007-10-17 Portela & Ca Sa 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives
GB0700773D0 (en) * 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
US20120022047A1 (en) 2009-04-02 2012-01-26 Glenmark Generics Ltd Process for the purification of eslicarbazepine acetate
UA106384C2 (ru) * 2009-07-27 2014-08-26 БИАЛ-ПОРТЕЛА энд КА., С.А. ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ 5H-ДИБЕНЗ/б,ф/АЗЕПИН-5-КАРБОКСАМИДА ДЛЯ ЛЕЧЕНИЯ ФИБРОМИАЛГИИ
WO2011045648A2 (en) 2009-10-12 2011-04-21 Matrix Laboratories Limited Process for preparing (s)-(-)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide and its esters thereof
WO2011091131A2 (en) * 2010-01-23 2011-07-28 Dr. Reddy's Laboratories Ltd. Eslicarbazepine acetate and its polymorphs
WO2011117885A1 (en) * 2010-03-23 2011-09-29 Intas Pharmaceuticals Limited Process for preparation of enantiomers of licarbazepine
EP2383261B1 (en) 2010-04-23 2013-09-04 Euticals GmbH Process for the asymmetric hydrogenation of ketones
WO2011138795A2 (en) * 2010-05-03 2011-11-10 Msn Laboratories Limited Process for preparing (s)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f] azepine-5-carboxamide
MX350531B (es) 2010-12-31 2017-09-08 BIAL PORTELA & Cª S A Granulados que comprenden acetato de eslicarbazepina.
WO2012121701A1 (en) * 2011-03-07 2012-09-13 Watson Laboratories, Inc. Process for the resolution of racemic (±)-10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide
ES2687678T3 (es) 2011-03-08 2018-10-26 Jubilant Life Sciences Limited Procedimiento para la preparación de (S)-(+)-10,11-dihidro-10-hidroxi-5H-dibenzo[b,f]azepina-5-carboxamida y ésteres de la misma mediante reducción enantioselectiva de 10,11-dihidro-10-oxo-5H-dibenzo[b,f]azepina-5-carboxamida
US9102963B2 (en) 2011-04-13 2015-08-11 Codexis, Inc. Biocatalytic process for preparing eslicarbazepine and analogs thereof
WO2013008194A2 (en) 2011-07-13 2013-01-17 Ranbaxy Laboratories Limited Process for the preparation and purification of eslicarbazepine acetate and intermediates thereof
US9750747B2 (en) 2011-08-26 2017-09-05 Bail-Portela & Ca, S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
CA2872975A1 (en) * 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
WO2014049550A1 (en) 2012-09-26 2014-04-03 Ranbaxy Laboratories Limited Process for the preparation of oxcarbazepine and its use as intermediate in the preparation of eslicarbazepine acetate
EP3240779B1 (en) * 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CN105384689B (zh) * 2014-12-24 2017-10-31 开封制药(集团)有限公司 一种改进的醋酸艾司利卡西平的合成方法
EP3064490A1 (en) 2015-03-06 2016-09-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate
CN105130899A (zh) * 2015-08-25 2015-12-09 安徽省新星药物开发有限责任公司 一种醋酸艾司利卡西平的合成方法
ES2903037T3 (es) 2015-12-18 2022-03-30 Jubilant Generics Ltd Formas de dosificación orales sólidas de eslicarbazepina
CN106588773B (zh) * 2016-11-10 2019-09-27 北京现代药物代谢研究院 一种脑靶向艾司利卡西平酯类前药及其应用
BR112021005955A2 (pt) 2018-09-28 2021-07-27 Griffith University agentes e métodos para modular atividade de patógeno

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH500196A (de) * 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
CH505101A (de) * 1969-03-31 1971-03-31 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
FI75561C (fi) * 1979-10-30 1988-07-11 Ciba Geigy Ag Foerfarande foer framstaellning av 5- karbamoyl-10-oxo-10,11-dihydro-5h-dibens/b,f/azepin och daertill noedvaendiga mellanprodukter.
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
DD218889B3 (de) * 1983-11-09 1992-11-05 Dresden Arzneimittel Verfahren zur herstellung neuer 5-carbamoyl-10,11-dihydro-5h-dibenz|b,f¨azepine
SU1650008A3 (ru) * 1988-07-12 1991-05-15 Циба-Гейги Аг (Фирма) Способ получени 1,5-дибенз[ @ , @ ]-азепин-5-карбоксамида
US5466683A (en) * 1994-08-25 1995-11-14 Teva Pharmaceutical Industries Ltd. Water-soluble analogs of carbamazepine

Also Published As

Publication number Publication date
SI0751129T1 (en) 1999-02-28
DE69600985T2 (de) 1999-04-15
HUP9900172A3 (en) 1999-11-29
PL324313A1 (en) 1998-05-25
DK0751129T3 (da) 1999-08-02
DK0751129T6 (da) 2020-05-25
PT101732A (pt) 1997-01-31
NL300406I1 (nl) 2009-11-02
DE69600985T3 (de) 2020-09-24
KR19990028464A (ko) 1999-04-15
ES2124612T3 (es) 1999-02-01
AR003962A1 (es) 1998-09-30
DE69600985D1 (de) 1998-12-24
TR199701734T1 (xx) 1998-04-21
DE122009000049I1 (de) 2010-01-21
CA2180301A1 (en) 1996-12-31
AU705388B2 (en) 1999-05-20
JP3852984B2 (ja) 2006-12-06
HU221382B1 (en) 2002-09-28
WO1997002250A1 (en) 1997-01-23
EP0751129B1 (en) 1998-11-18
CN1070853C (zh) 2001-09-12
HUP9900172A2 (hu) 1999-04-28
US5753646A (en) 1998-05-19
KR100376603B1 (ko) 2003-12-18
JPH09110836A (ja) 1997-04-28
ES2124612T7 (es) 2020-07-20
BR9602933A (pt) 1998-04-28
JP2004256516A (ja) 2004-09-16
EP0751129B3 (en) 2020-05-13
EP0751129A1 (en) 1997-01-02
PL185476B1 (pl) 2003-05-30
PT101732B (pt) 1997-12-31
CN1193965A (zh) 1998-09-23
BRPI9602933B8 (pt) 2022-01-18
AU6310696A (en) 1997-02-05
CA2180301C (en) 2004-02-10
DE122009000049I2 (de) 2011-01-13
RU2168502C2 (ru) 2001-06-10
ES2124612B5 (en:Method) 2019-01-28
BR9602933B1 (pt) 2013-06-11
ATE173468T3 (de) 1998-12-15
FR09C0040I1 (en:Method) 2009-10-30

Similar Documents

Publication Publication Date Title
FR09C0040I2 (en:Method)
BR122012014331A2 (en:Method)
IN184751B (en:Method)
EP0776697A3 (en:Method)
IN187598B (en:Method)
CH0741373H1 (en:Method)
IN184769B (en:Method)
IN180249B (en:Method)
IN188238B (en:Method)
IN184539B (en:Method)
IN185107B (en:Method)
IN182154B (en:Method)
IN183400B (en:Method)
IN184752B (en:Method)
ECSMU950059U (en:Method)
CN3032522S (en:Method)
EP0764821A3 (en:Method)
CN3032332S (en:Method)
CN3032390S (en:Method)
CN3032568S (en:Method)
CN3031742S (en:Method)
CN3031655S (en:Method)
CN3031350S (en:Method)
CN3032692S (en:Method)
CN3033225S (en:Method)